Checklist for Remicade (infliximab) Referral

Required documentation for all initial referrals

Patient	·	DOB	Date	□ New Start □ Maintenance					
Please	return completed checklist and ch	ecklist items for an in	fusion referral:						
	Patient demographics (e.g. address, phone number, SSN, etc.)								
	Insurance information and copy of insurance card(s). Please indicate the insurance that is primary, and the insurance that is secondary, if applicable, and the subscriber's date of birth. o If insurance requires prior authorization, please provide the phone number and allow up to 15-30 days for this to be completed by one of our Infusion Coordinators.								
	Signed and completed Remicade St • Standard Order forms are of	•	•						
	Supporting clinical MD notes to inccontraindications to conventional t	• •	· · · · · · · · · · · · · · · · · · ·						
	 Required Hepatitis Antibody, or Hepat 	ning results: PPD (with s screening (within 1 ye titis B Core Antibody re last 60 days: ESR/CRP	<i>ear)</i> : Hepatitis B Surf	FERON Gold Test <i>(within 3 years)</i> face Antigen, Hepatitis B Surface					
	Please indicate name and direct phany additional information: O Name:		act within your office	that we can speak with to obtain					
	o Phone Number:								
Paperwork can be faxed or emailed to (404) 528-1852, argpriorauth@articularishealthcare.com									
	Prior Authorization	Arthritis & Rheumat Department will as (404) 255-5956 exte	ssist you with any	questions at					
documo	s & Rheumatology of GA services wi entation to the patient's insurance of ther information is required. We wil le co-pay assistance as required. Th	company for eligibility. Il review financial resp	Our Prior Authoriza onsibility with the pa	ition Department will notify you if					
Δrth	uritis & Rheumatology of GA Use Only	Evisting Datient Ves	No Physician						

Standard Orders for Remicade (infliximab) Administration

Patient	DOB	Dat	te						
*NOTE: Patient is ineligible to receive Remic	ade if they have suspecte	d infectious process	or is receiv	ing antibiotic for active					
infectious process due to the possibility of d		•		=					
Indication: <i>Please indicate the highest level</i>	of specificity.								
□ K50.0 Crohn's Disease (small	☐ K51.9Ulcerative	Colitis,	□ K60.3	Anal Fistula					
intestine)	Unspecified	,							
☐ K50.1Crohn's Disease (large	☐ K51.5Left-sided	Ulcerative	□ Other IC	D-10 Code					
intestine)	(chronic) Colitis								
☐ K50.8 Crohn's Disease (small and		erative (chronic)							
large intestine)	Colitis								
☐ K63.2 Fistula of intestine	□ K51.0Universal	Ulcerative							
Listona	(chronic) Pancolitis								
History: □ Inadequate response to DMARDS		□ Unable to tolera	te DMARDS						
□ Rapid 3	□ Swollen/tender joints								
□ ESR/CRP	□ Progressive erosive arthropathy								
☐ HBsAg, HBsAb, HB core Ab, HCAb	□ Recent or upcoming surgery								
<u> </u>		□ Recent or upcor	ning surgery	/					
☐ History of skin cancer									
Orders: □ Standard Order Protocol:									
 Confirm current PPD, Tspot, or CXR 									
• •									
Obtain patient weight each visit	Confirm HBsAg, HBsAb, HB core Ab, HCAb negative Obtain nations weight each visit								
 Evaluate patient for active infection 	ns nrior or uncoming surg	ical procedures me	dication all	ergies congestive heart failure					
		icai procedures, inc	dication and	ergies, congestive heart randre,					
	 or any current health concerns as noted on Infusion Record Baseline vitals will be obtained prior to administration, hourly during infusion and at the end of the infusion. Vital signs will 								
	be obtained more frequently if patient's condition warrants it.								
			es 1-4. and f	for patients receiving pre-meds					
	• Titrate infusion over 2 hours as recommended in Janssen Infusion Guide for doses 1-4, and for patients receiving pre-meds due to previous infusion reaction. After dose 4, titrate infusion over 1 hour as tolerated.								
If infusion reaction occurs, slow or				r Articularis Healthcare Policy					
and Procedure Manual.	•			•					
Discharge instructions to include po	ossible infusion side effect	s and follow-up app	oointment s	chedule					
Dose:									
☐ Remicade (infliximab)m	g/kg in Normal Saline IV								
Frequency:									
☐ Initiation of Remicade to be admi	inistered at week(s) 0, 2, a	and 6							
☐ Maintenance dose every									
Premedicate:	-								
□ No pre-med									
□ Pre-medicate x 1 dose 30 minutes prior to	each infusion with:								
□ 1000 mg Acetaminophen PO		□ 125mg Solu-Me	drol IV □ C	Other					
-									
Additional orders/comments:									
Practice Name:		NPI:							
Physician Name:		State License:							
Physician Signature:		DEA #.							
, 5.6.6.1. 5.6.1.6.6.		DEA #:							
Date:		UPIN:							